2009 IoN News Archive
- Grant for research into new epilepsy treatments
- Professor Martin Rossor has been recognised by the The Alzheimer's Association
- Drug discovery collaboration on inclusion body myositis
- PDS awards Training Fellowship to Institute of Neurology researcher to understand how the brain controls Parkinson’s symptoms
- Alan Thompson to lead UCL Partners Neurological Disorders theme
- World MS Day - Wednesday 27th May - Global initiative to highlight Multiple Sclerosis
- Queen Square leads on new UK recommendations for bladder management which can dramatically improve quality of life in Multiple Sclerosis
- John Hardy most-cited Alzheimer's disease researcher in the UK
- Prestigious awards for Institute researchers
- Drug study offers hope for Alzheimer’s treatment
- Brain activity predicts our choices
- Professor George du Boulay CBE, FRCR, FRCP
- Brain awareness week: the impact of UCL research
- Parkinson's-linked mutation makes neurons vulnerable to calcium-induced death
- Second round of NIHR Senior Investigators announced
- 'Mind-Reading' Experiment Highlights How Brain Records Memories
- Anti-malaria drug does not appear to help with human prion diseases.
- UCL Partners is one of UK’s first Academic Health Science Centres
- "Opening doors for patients with MS"
- Are we as decisive as we think?
- "Magnets stop the nightmare of tinnitus, researchers say."
- Prestigious award for Professor Hugh Bostock
- Untangling the Brain
- Young UCL Investigator Award in neuroimaging techniques
- Brain disease "resistance gene" could offer insights into CJD
- Neurology: A Queen Square Textbook
- Headache: annual evidence update
- Roads closed for powerful MRI scanner delivery
- Long-term risks lower for surgical treatment of carotid stenosis
- Memorandum of collaboration signed
- Professor John Hardy joins the ranks of science greats
- Drug study offers hope for Alzheimer's treatment
- Prestigious award for Professor David Miller
- Magnets stop the nightmare of tinnitus, researchers say.
- Brain activity predicts our choices
- Jon Driver Award
- Professor Sander named recipient of the American Epilepsy Society 2009 Clinical Science Award
- Study highlights effect of brain waves on human behaviour
- New podcast describes the significance and impact of highly cited paper
- NIH Grant for research into inherited neuropathies
- How the brain knows a dog is a dog: concept acquisition in the human brain
- Prof Elizabeth Fisher elected member of the European Molecular Biology Organization (EMBO)
- Locating literacy in the brain
- Dopamine enhances expectation of pleasure in humans
- Queen Square scientists question memory theory
- IoN scientist to front Alzheimer’s Research Trust national appeal
- New doors open to the understanding of the origin of brain tumours
Published: Jul 8, 2013 2:00:00 PM
Published: Jul 5, 2013 5:29:00 PM
Published: Jun 5, 2013 3:54:00 PM
Published: Jun 5, 2013 2:24:00 PM
Drug discovery collaboration on inclusion body myositis
2 July 2009
The UCL MRC Centre for Neuromuscular Diseases (CNMD) based at Queen Square, Senexis Limited, and the Oxford MRC Functional Genomics Unit (FGU) announced today that they have agreed to collaborate on the discovery of novel therapeutics for Inclusion Body Myositis (IBM).
Inclusion body myositis (IBM) is the most common acquired muscle disease in people over 50 years old, currently there is no effective treatment. The collaboration will exploit the three organisations’ combined resources and intellectual property to accelerate the discovery of new compounds for the potential treatment of inclusion body myositis.
Mark Treherne, Senexis’ Chief Executive, commented: “We are pleased to be collaborating with the MRC at Oxford and at University College, London. Inclusion body myositis receives comparatively little attention and there is a significant medical need for therapeutic intervention for this condition. We now look forward to being able to accelerate the discovery of molecules with future therapeutic potential”.
Professor Sattelle said: “This MRC funding will assist in bringing the impact of basic research to patients more quickly.”
|read more >> MRC Press Release|